MOTS-c dosage: what the research actually supports

Last updated 2026-07-25

Is there an official MOTS-c dosage for humans?

No. There is no FDA-approved MOTS-c product, no package insert, and no dosage the agency has reviewed for safety or effectiveness in people. Check Drugs@FDA and you will not find it listed ^[1]. Every number you see online, including anything we publish here, comes from one of three places: the animal research doses scaled down by body weight, the practices of compounding pharmacies working from provider orders, or informal community reporting that has no clinical trial behind it. That matters because the foundational MOTS-c paper, published in Cell Metabolism in 2015, tested the peptide in mice, not humans. Researchers found that MOTS-c "promotes metabolic homeostasis and reduces obesity and insulin resistance" in mouse models, using injected doses in the range of 15 mg/kg of body weight ^[2]. Scaling a mouse mg/kg dose to a human isn't a simple ratio conversion your pharmacist can just do at the counter. Species differ in metabolic rate, peptide clearance, and receptor sensitivity, and none of that has been mapped in a human pharmacokinetic study for MOTS-c that we could find in the published literature. So when someone asks for "the" MOTS-c dosage, the honest answer is: nobody has run the trial that would give you one. What follows is a description of the doses that show up in animal work and in current compounding practice, clearly labeled as such.

What is a typical MOTS-c dosage chart based on (mg per day, per week)?

Most dosage charts circulating for MOTS-c describe a range of roughly 5 mg to 10 mg per week, split into smaller subcutaneous injections taken several times a week rather than one large weekly dose. A common pattern in provider protocols is 0.5 mg to 1 mg per injection, 3 to 5 times weekly, for a cycle of 8 to 12 weeks. None of this comes from a published human dose-ranging study. It is extrapolated from the animal literature and adjusted by clinicians based on general peptide-handling experience. Here is how that breaks down when people ask about a "mots-c 10mg" vial specifically, which is the most common concentration compounding pharmacies dispense:

These numbers describe common compounding practice, not a validated clinical dosage. Treat this table as a map of what's out there, not a recommendation. If you want the arithmetic done for your specific vial and dilution, a MOTS-c dosage calculator can walk through the math, but the calculator doesn't validate that the dose itself is medically correct, only that the volume matches the number you typed in.

How often should MOTS-c be dosed per day or per week?

Most protocols call for dosing 3 to 5 days a week rather than daily, with rest days built in. Some providers run a daily low-dose schedule for shorter stretches, then take a full week off. There is no human trial comparing daily versus every-other-day dosing for MOTS-c, so frequency choices in practice are driven by general peptide pharmacology reasoning (shorter-acting peptides often get dosed more frequently) rather than MOTS-c-specific data. The mouse studies that anchor this field used daily intraperitoneal injections in most of the metabolic work ^[2][3]. That's a controlled lab setting with a specific peptide half-life and route of administration, and it doesn't automatically justify a daily subcutaneous injection schedule in a person. A 2018 Cell Metabolism paper found that MOTS-c translocates to the nucleus specifically under metabolic stress conditions like glucose restriction or oxidative stress, suggesting its activity may be state-dependent rather than simply dose-dependent ^[4]. If that mechanism holds in humans, a protocol that pairs dosing with exercise or fasting windows might matter more than raw frequency, but that's a mechanistic hypothesis, not a tested recommendation. For the mechanics of drawing up a dose, timing it around meals or workouts, and injection technique, see how to take MOTS-c peptide and best time of day to take MOTS-c peptide.

What does the human evidence actually show, versus the animal data?

Almost none of the MOTS-c literature is human clinical trial data. A 2023 review in Frontiers in Endocrinology calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation," and that word, promising, is doing real work: it signals early-stage, not established ^[1]. The review summarizes years of cell and animal findings pointing toward metabolic, muscular, and cardiovascular effects, but it does not report human dosing trials because there aren't any to summarize. Specific examples of what "promising" actually means in the literature: MOTS-c reduced obesity and insulin resistance in mice fed a high-fat diet ^[2]. It relieved hyperglycemia and insulin resistance in a rodent model of gestational diabetes ^[5]. It suppressed ovarian cancer progression in a study using cell lines and mouse xenografts, working through a mechanism involving USP7-mediated protein regulation ^[6]. It attenuated muscle atrophy from immobilization in a rodent model by suppressing lipid infiltration into muscle tissue ^[7]. Every one of these is real, peer-reviewed work. None of them is a human trial, and none establishes a human dose. A 2023 Metabolites paper titled "MOTS-c Functionally Prevents Metabolic Disorders" is again describing preclinical mechanisms, not clinical outcomes in patients ^[8]. If you're evaluating MOTS-c against the hype, the honest framing is: strong, consistent mechanistic and rodent signal across a dozen-plus tissue systems, paired with an almost complete absence of human pharmacokinetic or efficacy data. That gap is the story right now, not a footnote to it.

Is MOTS-c really "exercise in a pill"? What does the research show about that claim?

"Exercise in a pill" is a marketing shorthand, not a finding any cited paper actually makes. The real research shows MOTS-c levels rise with exercise and the peptide participates in some of the same cellular stress-response pathways that exercise triggers, which is genuinely interesting biology. It does not show that injecting MOTS-c reproduces the cardiovascular, muscular, and metabolic adaptations of actually training. A 2022 review in Diabetes & Metabolism Journal, titled "Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)," describes MOTS-c as part of the mitohormesis response, the idea that mild mitochondrial stress (like the stress of a workout) triggers adaptive signaling ^[9]. A separate 2021 paper in Biochimica et Biophysica Acta reviewed mitochondrial-derived peptides and exercise more broadly, again describing correlation and mechanism, not a controlled trial showing MOTS-c injections substitute for training . Separately, a 2024 iScience paper found MOTS-c modulates skeletal muscle function by directly binding and activating an enzyme called CK2 ^[8], and a 2021 paper in the American Journal of Physiology found MOTS-c reduces myostatin and muscle atrophy signaling in a rodent model . Those are mechanistic and animal findings about muscle biology, not evidence that a person injecting MOTS-c gets fitter without moving. If you want the cardiovascular and metabolic benefits, the training still has to happen. Nothing in the current literature supports skipping it.

What's a realistic MOTS-c dosage protocol length (cycle length)?

Most provider-guided protocols run 8 to 12 weeks, followed by a break of 4 or more weeks before restarting. This cycling pattern is standard peptide practice borrowed from other research peptides, not something derived from a MOTS-c-specific human trial establishing an ideal cycle length. The reasoning providers give usually centers on avoiding the body adapting to a chronically elevated exogenous peptide signal, plus giving time to reassess bloodwork (fasting glucose, insulin, lipid panel) between cycles. Whether that reasoning holds up for MOTS-c specifically hasn't been tested. If you're planning a cycle, MOTS-c cycle length covers the tradeoffs providers weigh in more detail, and it's worth reading before you commit to a 12-week run based on a forum post.

How is MOTS-c legally obtained, and does that affect dosage?

MOTS-c is not FDA-approved for any indication, so it isn't dispensed with an FDA-reviewed label or dosage instructions the way a drug like metformin is. Where it's available, it typically comes through 503A or 503B compounding pharmacies, which operate under different legal frameworks than manufacturers of approved drugs. Section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, governs traditional pharmacy compounding for an individual patient with a valid prescription ^[10]. Section 503B covers outsourcing facilities that can compound in larger batches under different rules ^[11]. Whether a substance can legally be used in compounding at all depends on FDA's bulk drug substance determinations under 21 CFR 216.23 (the 503A bulks list) and 21 CFR 216.24 (the 503B bulks list) ^[12][13]. FDA's own bulk drug substances page for 503A explains that a substance's inclusion or exclusion from these lists is an active, evolving determination, not a permanent label ^[3]. This legal structure is exactly why dosage varies so much between sources. A prescription from a provider working with a compounding pharmacy comes with a dose the prescriber selected, generally informed by the animal literature and clinical judgment, and the pharmacy's compounding label reflects that specific order rather than a universal standard dose. That's also why we'd point you toward the MOTS-c overview page if you want the full picture of sourcing and legal status before you look at a chart of milligrams.

What are the risks of getting MOTS-c dosage wrong?

The honest answer is that we don't have good human safety data to define "wrong" precisely, which is itself the risk. Without human dose-ranging trials, nobody has established a clear maximum tolerated dose, a minimum effective dose, or the injection-site and systemic side effect profile you'd expect from an FDA-reviewed label. A 2026 Sports Medicine paper reviewing the safety and efficacy of approved and unapproved peptide therapies used in musculoskeletal and athletic contexts is a useful frame here: it treats MOTS-c as part of a wider category of unapproved peptides where safety and efficacy data lag behind athlete and consumer interest ^[14]. Practical risks that follow from that gap: dosing based on a mouse mg/kg extrapolation that may not hold in humans, batch-to-batch variability in compounded product purity and concentration, and no standardized injection-site or systemic monitoring protocol. None of this means MOTS-c is dangerous. It means the margin of safety hasn't been mapped the way it has for an approved drug, so conservative dosing, real bloodwork before and during use, and working with a provider who reviews your case rather than a chart you found online, are the practical guardrails available right now.

What other conditions is MOTS-c dosage being studied for, beyond metabolic health?

The research base is broader than metabolism, and it's almost entirely preclinical. Cardiovascular: a 2025 review in Cardiovascular Drugs and Therapy examined MOTS-c's potential role in diabetic cardiomyopathy ^[15]. Lung injury: a 2025 Redox Biology paper found MOTS-c attenuated lung ischemia-reperfusion injury in an animal model via a nuclear translocation mechanism ^[4][16], and a separate 2023 European Journal of Pharmacology paper found it suppressed ferroptosis and reduced acute lung injury from myocardial ischemia reperfusion ^[17]. Musculoskeletal: a 2023 Frontiers in Physiology paper reviewed MOTS-c's role in bone metabolism regulation ^[18], and a 2025 Free Radical Biology & Medicine paper found it attenuated cartilage degradation in an osteoarthritis model through an Nrf2-dependent pathway ^[19]. Infectious disease: a 2024 paper in Gut found MOTS-c has an antiviral role during hepatitis B infection through a mitochondrial remodeling mechanism ^[20]. Reproductive and endocrine: the 2022 Pharmacological Research paper on gestational diabetes ^[5] and the 2024 Advanced Science paper on ovarian cancer ^[6] both fall here. None of these studies were designed to establish a human dose; each used a dosing regimen appropriate to its specific animal or cell model, and those regimens differ from each other. If MOTS-c ever moves toward a human indication, it's not clear yet which of these systems, metabolic, cardiovascular, muscular, would define the dose that gets tested first.

How does MOTS-c dosage compare to how other mitochondrial-derived peptides are dosed?

MOTS-c belongs to a small family of mitochondrial-derived peptides, alongside humanin and the SHLP (small humanin-like peptide) series, and none of them have an FDA-approved human dosage either. A 2021 review in Biochimica et Biophysica Acta covering mitochondrial-derived peptides and exercise treats MOTS-c as one part of a broader signaling family that responds to exercise stress , and dosing conventions across this family in animal research tend to use similar mg/kg ranges, which is more a reflection of shared lab practice than proven equivalence in effect. One cautionary note worth flagging: a 2018 paper in Rejuvenation Research titled "Mitochondrial-Derived Peptides Exacerbate Senescence" found a context where a peptide in this family had an effect opposite to the anti-aging narrative often attached to the class ^[21]. That's a reminder that "mitochondrial-derived peptide" is not a synonym for "good for you in all contexts and at all doses." Context, dose, and tissue type all seem to matter, and we don't yet have the human data to specify any of the three precisely for MOTS-c.

Where can you get MOTS-c with provider oversight rather than guessing at a dosage chart?

If you're going to use MOTS-c at all given the evidence gaps described above, provider oversight is the difference between an informed decision and a guess copied from a forum. MOTS-c Co reviews provider protocols and points readers toward a fulfilling pharmacy partner that compounds under the 503A/503B framework described earlier, rather than offering a fixed dosage chart divorced from your bloodwork and history. That's a sourcing and oversight function, not a manufacturing one. MOTS-c Co doesn't compound or manufacture MOTS-c itself; it reviews providers and points to where compounding happens legally. If you want the injection mechanics and site rotation that go with whatever dose a provider settles on, MOTS-c injection sites covers that ground directly.

Frequently asked questions

What is the standard MOTS-c dosage per day?

There is no standard, FDA-established daily dosage. Common provider protocols use 0.5 mg to 1 mg per injection, given 3 to 5 times a week rather than every single day, based on animal dosing extrapolation and clinical judgment rather than a human dose-ranging trial.

How much is a typical MOTS-c 10mg vial supposed to last?

At a common dilution of 10 mg into 2 mL of bacteriostatic water, a 0.5 mg dose per injection (0.1 mL) given 3 to 5 times weekly typically lasts 2 to 3 weeks. This depends entirely on the dilution and dose your provider specifies, which varies by protocol.

Is there an official MOTS-c dosage chart approved by the FDA?

No. MOTS-c has no FDA-approved indication and doesn't appear in the Drugs@FDA database. Any dosage chart in circulation, including ones on this site, reflects animal research doses and common compounding practice, not an agency-reviewed standard.

Does MOTS-c really work like exercise in a pill?

No study shows injecting MOTS-c reproduces training adaptations. The research shows MOTS-c is part of the mitohormesis signaling that exercise triggers, per a 2022 Diabetes & Metabolism Journal review, which is a mechanistic overlap, not proof the peptide substitutes for exercise itself.

What was the original MOTS-c dosage used in the 2015 Cell Metabolism study?

The foundational 2015 Cell Metabolism paper used injected doses around 15 mg/kg body weight in mice to show reduced obesity and insulin resistance. That's a mouse dose in a controlled lab setting, and it does not convert directly into a human milligram dose.

How often per week should MOTS-c be injected?

Most protocols call for 3 to 5 injections per week rather than daily dosing, though some run daily for short stretches. This frequency is based on general peptide pharmacology practice and provider judgment, since no published human trial has compared dosing frequencies for MOTS-c.

Can MOTS-c dosage be legally prescribed in the United States?

MOTS-c can be compounded by 503A or 503B pharmacies under the Food, Drug and Cosmetic Act framework (21 U.S.C. 353a) if it qualifies under FDA's bulk drug substance lists (21 CFR 216.23, 216.24). It has no FDA-approved indication, so any use is prescribed off-label by a provider, not sold as an approved drug.

What's the difference between a mots-c dosage chart for research use versus human use?

Research-use charts typically report mg/kg doses given to mice or in cell culture concentrations, used to study mechanisms. Human-use protocols from providers convert those concepts loosely into fixed milligram doses (like 0.5 mg per injection), but that conversion isn't a validated pharmacokinetic translation.

How long should a MOTS-c dosage cycle last?

Common provider protocols run 8 to 12 weeks followed by a 4-week or longer break before restarting. This cycling approach is borrowed from broader peptide practice rather than derived from a MOTS-c-specific trial testing optimal cycle length.

Is a higher MOTS-c dose more effective?

There's no human data showing a dose-response curve for MOTS-c, so higher isn't established as better. Animal studies used specific mg/kg doses tied to their experimental design; extrapolating that more milligrams equals more benefit in a person is not supported by any published human trial.

Are there side effects at typical MOTS-c dosages?

Human safety data is thin. A 2026 Sports Medicine review treats MOTS-c as part of a category of unapproved peptides where safety and efficacy data lag behind interest in use, meaning a clear side effect profile at specific doses hasn't been established through controlled human trials.

Does MOTS-c dosage differ for muscle-focused versus metabolic-focused goals?

Providers sometimes adjust dosing intent based on published mechanisms, since animal studies link MOTS-c to muscle atrophy suppression, myostatin reduction, and metabolic homeostasis through different pathways. But no human trial has tested whether a muscle-specific versus metabolic-specific dosage split actually produces different outcomes in people.

Sources

1. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation, reflecting early-stage rather than established evidence
2. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c reduced obesity and insulin resistance in mice using injected doses around 15 mg/kg body weight
3. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate gene expression specifically in response to metabolic stress
4. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Section 503A of the FDCA governs traditional pharmacy compounding for individual patients under a valid prescription
5. eCFR, 21 CFR 216.24: 21 CFR 216.24 establishes the bulk drug substances list applicable to 503B outsourcing facility compounding
6. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's determination of whether a substance can be used in 503A compounding is an active, evolving regulatory process
7. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieved hyperglycemia and insulin resistance in a rodent model of gestational diabetes mellitus
8. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppressed ovarian cancer progression in a study using a USP7-mediated protein degradation mechanism
9. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating the enzyme CK2
10. eCFR, 21 CFR 216.23: 21 CFR 216.23 establishes the final bulk drug substances list applicable to 503A pharmacy compounding
11. Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product in the Drugs@FDA database
12. PubMed, American Journal of Physiology 2024 (PMID 38170165): MOTS-c attenuated immobilization-induced skeletal muscle atrophy in a rodent model by suppressing lipid infiltration
13. PubMed, Sports Medicine 2026 (PMID 41966639): A review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance frames MOTS-c among unapproved peptides with limited human safety and efficacy data
14. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): A 2025 review examines MOTS-c's potential role in diabetic cardiomyopathy
15. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuated lung ischemia-reperfusion injury in an animal model via a nuclear translocation mechanism
16. PubMed, Frontiers in Physiology 2023 (PMID 37200834): MOTS-c's role in bone metabolism regulation is reviewed as a preclinical mechanistic finding
17. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppressed ferroptosis and reduced acute lung injury induced by myocardial ischemia reperfusion via PPARgamma signaling
18. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuated cartilage degradation in an osteoarthritis model through an Nrf2-dependent mechanism
19. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): MOTS-c is described as part of the mitohormesis response that links exercise-induced mitochondrial stress to adaptive signaling
20. PubMed, Gut 2024 (PMID 37788894): MOTS-c has an antiviral role during hepatitis B infection through a mitochondrial remodeling mechanism
21. PubMed, Rejuvenation Research 2018 (PMID 30058454): A study found mitochondrial-derived peptides can exacerbate senescence in certain contexts, countering a uniformly anti-aging narrative
22. PubMed, American Journal of Physiology 2021 (PMID 33554779): MOTS-c reduced myostatin and muscle atrophy signaling in a rodent model
23. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): A review of mitochondrial-derived peptides and exercise treats MOTS-c as part of a broader signaling family responsive to exercise stress